Roche set to unveil fresh Alzheimer’s disease findings from its combined pharmaceutical and diagnostics portfolio at AAIC

Roche has confirmed it will bring new data from its Alzheimer’s disease portfolio to the Alzheimer’s Association International Conference 2026 in London, running from 12 to 15 July. The findings illustrate how Roche is pushing forward the development of next-generation medicines and diagnostic tools in pursuit of its goal to slow, halt, or ultimately prevent Alzheimer’s disease from progressing. A total of 18 oral and poster presentations are scheduled across the event. Key highlights include five oral presentations within a trontinemab Featured Research Session, an oral Perspectives Session examining neuroimmune targets such as NLRP3 in neurodegenerative disease, and a series of presentations focused on the role of Roche’s Elecsys pTau217 and pTau181 blood tests in supporting Alzheimer’s diagnosis in clinical practice.

“We aim to bring together advanced diagnostics and transformative medicines, with the goal of benefitting many Alzheimer’s patients through earlier detection and intervention,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our presentations at AAIC will feature data from our expanding Alzheimer’s disease portfolio, including investigational trontinemab, neuroinflammatory approaches and blood-based diagnostics.”

“With the approval of Elecsys pTau217, our third Alzheimer’s blood test, across both primary and secondary care, we are making timely and definitive diagnosis more accessible than ever before,” said Matt Sause, CEO of Roche Diagnostics. “For too long, this has been out of reach for the vast majority of patients. As a result, millions have been left without the answers, care and support they need. That is now changing, as blood-based testing transforms the diagnosis of Alzheimer’s disease.”

---

---

Related Topics and Keywords

Alzheimer's disease, Alzheimer’s, Roche